Dexcom
DXCM
$91.06
+0.26%
DexCom, Inc. is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes, offering an alternative to traditional blood glucose meters. As a market leader in the CGM space, DexCom differentiates itself through its innovative sensor technology and integration with insulin pumps from partners like Insulet and Tandem, enabling automated insulin delivery. The current investor narrative centers on the company's expansion into the over-the-counter (OTC) market with its Stelo monitor, which recently received FDA clearance for pediatric use, broadening its addressable market. Additionally, the stock has shown strong momentum, with a 20.9% price increase over the past year, driven by robust revenue growth and optimism about future product launches and market penetration.…
DXCM
Dexcom
$91.06
Related headlines
Investment Opinion: Should I buy DXCM Today?
Based on the analysis, DXCM is rated as a Buy. The company's strong revenue growth of 15% YoY, expanding market opportunities, and a PEG ratio of 0.67 suggest that the stock is undervalued relative to its growth potential. The analyst consensus is a Strong Buy with an average target price of $94.12, implying a 3.6% upside, but the high target of $115 offers 26.6% upside if the company executes well.
Sign up to view all
DXCM 12-Month Price Forecast
The AI assessment is bullish on DXCM, driven by solid revenue growth, a favorable PEG ratio, and positive analyst sentiment. The company's expansion into pediatric markets provides a new growth catalyst, and its strong profitability metrics support continued investment. However, the high valuation multiples and competitive pressures warrant a medium confidence level. If revenue growth accelerates or the stock pulls back to a more attractive valuation, the stance would be upgraded to high confidence. Conversely, any signs of growth deceleration or competitive losses would lead to a downgrade.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dexcom's 12-month outlook, with a consensus price target around $94.12 and implied upside of +3.4% versus the current price.
Average Target
$94.12
0 analysts
Implied Upside
+3.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$79 - $115
Analyst target range
The target price range spans from a low of $79.00 to a high of $115.00, with the average at $94.12. The wide spread of $36 between the low and high targets reflects significant uncertainty about the company's future performance. The high target of $115 implies a 26.6% upside, likely assuming successful expansion of Stelo into pediatric markets and continued strong adoption of CGM systems. The low target of $79 suggests a 13.0% downside, possibly pricing in competitive pressures from Abbott and Medtronic or slower-than-expected market growth. The recent ratings have been predominantly positive, with no downgrades, indicating that analysts are confident in DexCom's growth trajectory, though the wide range highlights the inherent risks in the medical device sector.
Bulls vs Bears: DXCM Investment Factors
DexCom presents a compelling growth story with strong revenue momentum, expanding market opportunities, and a PEG ratio suggesting undervaluation relative to growth. However, the stock trades at premium multiples, faces intense competition, and carries higher market risk due to its beta. Currently, the bull case has stronger evidence given the robust fundamentals and positive analyst sentiment, but the key tension lies in whether the company can maintain its growth trajectory to justify its valuation. If growth decelerates or competition intensifies, the stock could face significant downside, making the sustainability of growth the pivotal factor.
Bullish
- Robust Revenue Growth: Q1 2026 revenue grew 15.05% YoY to $1.19B, with sequential growth from $1.16B in Q2 2025 to $1.26B in Q4 2025, indicating sustained demand for CGM systems and successful market expansion.
- Undervalued on PEG Ratio: With a PEG ratio of 0.67, the stock trades at a discount to its expected earnings growth, suggesting the market is pricing in lower growth than the company is likely to deliver, offering upside potential.
- Strong Profitability Metrics: Gross margin stands at 60.1% and operating margin at 19.6%, reflecting efficient operations and pricing power, with net margin of 17.9% indicating solid bottom-line performance.
- Positive Analyst Sentiment: Analysts rate DXCM as a 'Strong Buy' with a mean recommendation of 1.32, and the average target price of $94.12 implies a 3.6% upside from the current price, with a high target of $115 offering 26.6% upside.
Bearish
- High Valuation Multiples: Trailing PE of 31.0x and forward PE of 29.1x are premium to the broader market, and the stock trades at 9.4x book value, leaving little room for error if growth decelerates.
- Intense Competition: Abbott and Medtronic are aggressive competitors in the CGM space, and any market share loss could pressure revenue growth, as evidenced by the wide analyst target range of $79 to $115.
- Beta and Market Sensitivity: With a beta of 1.41, DXCM is more volatile than the market, and a macro downturn or rising interest rates could lead to significant multiple compression, as seen in the 38.75% max drawdown.
- Dependence on Continued Growth: The stock's valuation relies on sustained double-digit revenue growth; any slowdown, such as from market saturation or reimbursement changes, could trigger a de-rating.
DXCM Technical Analysis
DexCom's stock is in a strong uptrend, with a 1-year price change of +20.96% and the current price of $90.82 sitting near the top of its 52-week range (54.11 to 92.59), at approximately 98% of the high. This positioning near the highs indicates strong bullish momentum, though it also suggests the stock may be overextended in the short term. The 52-week low of $54.11 was set in late April 2026, and the stock has since rallied significantly, reflecting a recovery from earlier weakness.
Beta
1.41
1.41x market volatility
Max Drawdown
-38.8%
Largest decline past year
52-Week Range
$54-$93
Price range past year
Annual Return
+20.9%
Cumulative gain past year
| Period | DXCM Return | S&P 500 |
|---|---|---|
| 1m | +9.1% | +2.7% |
| 3m | +24.0% | +1.0% |
| 6m | +24.9% | +12.0% |
| 1y | +20.9% | +18.9% |
| ytd | +36.9% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DXCM Fundamental Analysis
DexCom's revenue trajectory is robust, with the most recent quarter (Q1 2026) reporting revenue of $1.19 billion, a 15.05% year-over-year increase. This growth is consistent with the prior quarters: Q4 2025 revenue was $1.26 billion, Q3 2025 was $1.21 billion, and Q2 2025 was $1.16 billion, showing steady sequential growth. The company's revenue growth is driven by strong demand for its CGM systems, particularly the G7 series, and the expansion into the OTC market with Stelo. The growth rate has been stable, indicating a mature but still expanding market.
Quarterly Revenue
$1.2B
2026-03
Revenue YoY Growth
+15.0%
YoY Comparison
Gross Margin
62.9%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DXCM Overvalued?
For valuation, I selected the PE ratio as the primary metric because DexCom is profitable, with a trailing PE of 31.01x and a forward PE of 29.07x. The forward PE is slightly lower, implying the market expects earnings growth, which is consistent with the company's positive outlook. The PEG ratio of 0.67 suggests the stock is undervalued relative to its growth rate, indicating that the market may be pricing in lower growth than the company is expected to deliver.
PE
31.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 23x~223x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks include a debt-to-equity ratio of 0.51, which is manageable but indicates leverage, and a current ratio of 1.88, providing adequate liquidity. The company's reliance on continued revenue growth is critical, as any slowdown could impact its ability to service debt and fund R&D. With a net margin of 17.9%, profitability is solid, but the high valuation multiples (PE 31x) leave little margin for error if earnings disappoint. Additionally, the company's free cash flow of $1.43B TTM is strong, but it is reinvested heavily in growth, limiting dividend potential (payout ratio 0%).
FAQ
The key risks for DXCM include: 1) Competitive risk from Abbott and Medtronic, which could erode market share and pressure pricing; 2) Regulatory risk, as changes in FDA policies or reimbursement rates could impact adoption; 3) Macro risk, given the stock's beta of 1.41, making it sensitive to market downturns; and 4) Execution risk, as the company must continue to innovate and expand into new markets like pediatrics to sustain growth. The most severe risk is a combination of these factors leading to a decline to the 52-week low of $54.11, a 40% drop from current levels.
The 12-month forecast for DXCM is positive, with a base case target of $90-$100 (50% probability), a bull case of $100-$115 (30% probability), and a bear case of $70-$80 (20% probability). The base case assumes continued 15% revenue growth and stable margins, while the bull case relies on successful pediatric expansion and market share gains. The bear case would occur if competition intensifies or regulatory issues arise. The most likely scenario is the base case, with the stock trading around the analyst average target of $94.12, offering modest upside. Investors should monitor quarterly earnings for signs of acceleration or deceleration.
DXCM's valuation is a mixed picture. On a trailing PE of 31x and forward PE of 29x, it appears expensive relative to the broader market, but the PEG ratio of 0.67 suggests it is undervalued when accounting for its expected growth. The stock trades at 9.4x book value and 5.6x sales, which are high, but these are typical for high-growth medical device companies. Compared to its own history, the forward PE is below its five-year average, indicating it is not at extreme levels. The market is pricing in continued double-digit growth, and if that materializes, the valuation is justified. However, any disappointment could lead to multiple compression.
DXCM is a good buy for growth investors with a long-term horizon, given its strong revenue growth of 15% YoY and a PEG ratio of 0.67, which suggests the stock is undervalued relative to its growth. The analyst consensus is a Strong Buy with an average target price of $94.12, implying a 3.6% upside, but the high target of $115 offers 26.6% upside. However, the stock trades at a premium PE of 31x, so it is not a value play. The biggest downside risk is a growth slowdown or competitive pressure, which could lead to a decline to the 52-week low of $54.11. Overall, it is a good buy for those who believe in the long-term growth of the CGM market and can tolerate volatility.
DXCM is more suitable for long-term investment due to its growth stage and volatility (beta 1.41). The company is in a growth phase with expanding market opportunities, but its stock price can be volatile in the short term, as seen in its 38.75% max drawdown. Long-term investors can benefit from the compounding growth of the CGM market and the company's innovation, but they should be prepared for fluctuations. A minimum holding period of 3-5 years is recommended to ride out volatility and capture the full growth potential. Short-term traders might find opportunities in the stock's momentum, but the high beta makes it risky for short-term speculation.